title: [Up-regulation of the sHLA-G5 level by human-mouse chimeric anti-IL-2R monoclonal antibody treatment in kidney transplantation].
abstract: OBJECTIVE
  To find whether the up-regulation of soluble human leucocyte antigen-G5 (sHLA-G5) levels is a new function mechanism of anti-interleukin-2 receptors (anti-IL-2R) monoclonal antibody treatment in kidney transplantation.
  
  
  METHODS
  A total of 215 recipients at our centre from January 2006 to December 2007 were divided into antibody use group (n = 141) and antibody non-use group (n = 74) and another healthy group (n = 69). The sHLA-G5 level in peripheral blood was detected by enzyme-linked immunosorbent assay (ELISA). And the expression of HLA-G5 was confirmed by Western blot and Real-time polymerase chain reaction (PCR).
  
  
  RESULTS
  sHLA-G5 levels was (56 ± 30) µg/L in using anti-IL-2 receptor monoclonal antibody before transplantation, It was higher than that before use antibody [(34 ± 20) µg/L], also higher than healthy group [(35 ± 17) µg/L] and antibody non-use group [(36 ± 19) µg/L, P < 0.05, respectively]. At Day 1, Day 4, Week 1, Week 2 post-transplantation, the level of sHLA-G5 of recipients with antibody use was significantly higher than that of those with antibody non-use. The values were as follows: (95 ± 35) µg/L vs (54 ± 16) µg/L, (131 ± 24) µg/L vs (75 ± 22) µg/L, (167 ± 44) µg/L vs (62 ± 17) µg/L, (172 ± 35) µg/L vs (45 ± 16) µg/L (all P < 0.01). And the results of Western blot and RT-PCR corresponded to those of ELISA.
  
  
  CONCLUSIONS
  The preoperative use of first dose of anti-IL-2R monoclonal antibodies results in the up-regulated level of sHLA-G5. Thus it is beneficial for protecting the kidney survival and reducing the risks of acute rejection.
authors.affiliation: Basic Research Laboratory, Organ Transplantation Center, No. 309 Hospital of PLA, Beijing 100091, China.
authors.forename: Li
authors.initials: L
authors.lastname: Xiao
authors.forename: Bing-yi
authors.initials: BY
authors.lastname: Shi
authors.forename: Yu
authors.initials: Y
authors.lastname: Gao
authors.forename: Xiu-yun
authors.initials: XY
authors.lastname: He
authors.forename: Xiao-guang
authors.initials: XG
authors.lastname: Xu
authors.forename: Yong
authors.initials: Y
authors.lastname: Han
authors.forename: Wen-qiang
authors.initials: WQ
authors.lastname: Zhou
authors.forename: Xiao-yun
authors.initials: XY
authors.lastname: Meng
authors.forename: Meng-xia
authors.initials: MX
authors.lastname: Han
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D016022:Case-Control Studies; D005260:Female; D059951:HLA-G Antigens / Q000378:metabolism*; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D015854:Up-Regulation; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D059951:HLA-G Antigens; D015375:Receptors, Interleukin-2